Pre-Market Analysis: Amarin Corp. PLC, Elan Corp. PLC, Cubist Pharmaceuticals
Inc., and Seattle Genetics Inc.
LONDON, September 16, 2013
LONDON, September 16, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
The U.S. equity market edged higher on Friday, September 13, 2013, with the
S&P 500, the Dow Jones Industrial Average and the NASDAQ Composite rising
0.27%, 0.49% and 0.17%, respectively. Shares in the healthcare sector mostly
ended on a higher note as the broader market advanced. The major movers in the
sector included Amarin Corp. PLC (NASDAQ: AMRN), Elan Corp. PLC (NYSE: ELN),
Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and Seattle Genetics Inc. (NASDAQ:
SGEN). All these companies are tracked by AAAResearchReports.com. Free
technical research on AMRN, ELN, CBST, and SGEN can be downloaded upon signing
Amarin Corp. PLC.'s stock ended flat on Friday, even as the broader market
ended higher. The company's shares vacillated between$6.49 and$6.71before
finishing the day at the previous day's closing price of$6.60. A total of
3.24 million shares were traded, which is below the daily average volume of
4.18 million. Amarin Corp. PLC.'s shares have advanced 13.40% in the last one
month, outperforming the S&P 500 which has gained 1.94% during the same
period. Furthermore, the company's stock is trading above its 50-day moving
average of $5.89. Sign up and read the complimentary report on AMRN at:
On Friday, Elan Corp. PLC's stock gained 0.46%, tracking gains in the broader
market. The company's shares ended the day at$15.45 after fluctuating
between$15.37 and$15.45. A total of 3.61 million shares were traded, which
is less than the daily average volume of 11.53 million. Elan Corp. PLC's
shares have advanced 13.10% in the last three months, compared to a gain of
3.77% in the S&P 500 during the same period. Additionally, the company's stock
is trading near its 52-week high of $15.92 as well as above its 50-day and
200-day moving averages of $15.02 and $12.33, respectively. The free report on
ELN can be downloaded by signing up now at:
Cubist Pharmaceuticals Inc.'s shares edged lower on Friday, extending their
losses from previous trading sessions. The company's shares traded between
$64.60 and $65.55 before finishing the day 0.22% lower at $64.79. A total of
0.60 million shares were traded, which is below the daily average volume of
1.04 million. Despite Friday's pullback, the company's shares have advanced
5.14% in the last one month and 29.14% in the previous three months, compared
to a gain of 1.94% and 3.77% in the S&P 500 during the respective periods.
Additionally, Cubist Pharmaceuticals Inc.'s stock is trading near its 52-week
high of $66.68 as well as above its 50-day and 200-day moving averages of
$60.08 and $49.60, respectively. A free report on CBST can be accessed by
Shares in Seattle Genetics Inc. edged higher on Friday, hitting a new 52-week
high of $48.61. The company's shares closed the day at $48.48, up 0.58% from
the previous day's price of $48.20. A total of 0.88 million shares were
traded, which is below the daily average volume of 1.00 million. The company's
shares have gained 18.01% in the last one month and 48.12% in the previous
three months, outperforming the S&P 500 during the respective periods.
Further, Seattle Genetics Inc.'s stock is trading above its 50-day and 200-day
moving averages of $41.30 and $33.73, respectively. Register with AAA Research
Reports and download research on SGEN for free at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by an analyst. However, we are only human and are prone
to make mistakes. If you notice any errors or omissions, please notify us
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through analysts, only reviewed
the information provided by Equity News Network in this article or report
according to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
SOURCE AAA Research Reports
Contact: + 1 (646) 396-9126 ; Contact Name: Peter F. Jones ;
Press spacebar to pause and continue. Press esc to stop.